Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 2/2008

01-06-2008 | Review

Murine cytomegalovirus regulation of NKG2D ligands

Authors: Tihana Lenac, Jurica Arapović, Luka Traven, Astrid Krmpotić, Stipan Jonjić

Published in: Medical Microbiology and Immunology | Issue 2/2008

Login to get access

Abstract

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that causes morbidity risk in immunologically suppressed and immunodeficient patients including congenital infections. Approaches to curb the consequences of HCMV infections are restricted by a lack of complete understanding of viral pathogenesis. The infection of mice with murine cytomegalovirus (MCMV) as a model of HCMV infection has been particularly useful in elucidating the role of innate and adaptive immune response mechanisms. A large number of cytomegalovirus genes modulate the innate and the adaptive host immune response. The products of several MCMV genes are involved in subverting the natural killer (NK) cell response by down-modulating cellular ligands for the NKG2D receptor expressed on NK cells and CD8+ T cells. Mutant viruses lacking these immunoevasion genes are attenuated with respect to virus growth in vivo. Given the importance of the NKG2D receptor in controlling both NK- and T cell-mediated immunity, it is of tremendous importance to understand the molecular mechanisms and consequences of viral regulation of the NKG2D ligands.
Literature
1.
Roizman B, Pellett PE (2001) The family Herpesviridae: a brief introduction. In: Knipe DM, Howley PM (eds) Virology. Lippincott Williams and Wilkins, Philadelphia, pp 2381–2397
2.
Reddehase MJ, Podlech J, Grzimek NK (2002) Mouse models of cytomegalovirus latency: overview. J Clin Virol 25(Suppl 2):S23–36PubMedCrossRef
3.
Jonjic S, Pavic I, Polic B, Crnkovic I, Lucin P, Koszinowski UH (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179(5):1713–7PubMedCrossRef
4.
Polic B, Hengel H, Krmpotic A, Trgovcich J, Pavic I, Luccaronin P, Jonjic S, Koszinowski UH (1998) Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188(6):1047–54PubMedPubMedCentralCrossRef
5.
Simon CO, Seckert CK, Grzimek NKA, Reddehase MJ (2006) Murine model of cytomegalovirus latency and reactivation: the silencing/desilencing and immune sensing hypothesis. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister Academic Press, Wymondham, pp 483–500
6.
Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ (2001) Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344(18):1366–71PubMedCrossRef
7.
Fowler KB, Stagno S, Pass RF (2003) Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289(8):1008–11PubMedCrossRef
8.
Jonjic S, Bubic I, Krmpotic A (2006) Innate immunity to cytomegloviruses. In: Reddehase MJ (ed) Cytomegaloviruses molecular biology and immunology. Caister Academic Press, Norwich, pp 285–320
9.
Reddehase MJ (2002) Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2(11):831–44PubMedCrossRef
10.
Krmpotic A, Messerle M, Crnkovic-Mertens I, Polic B, Jonjic S, Koszinowski UH (1999) The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med 190(9):1285–96PubMedPubMedCentralCrossRef
11.
Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319(6055):675–8PubMedCrossRef
12.
Degli-Esposti MA, Smyth MJ (2005) Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 5(2):112–24PubMedCrossRef
13.
Robbins SH, Bessou G, Cornillon A, Zucchini N, Rupp B, Ruzsics Z, Sacher T, Tomasello E, Vivier E, Koszinowski UH, Dalod M (2007) Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog 3(8):e123PubMedPubMedCentralCrossRef
14.
Kirwan SE, Burshtyn DN (2007) Regulation of natural killer cell activity. Curr Opin Immunol 19(1):46–54PubMedCrossRef
15.
Dimasi N, Moretta L, Biassoni R (2004) Structure of the Ly49 family of natural killer (NK) cell receptors and their interaction with MHC class I molecules. Immunol Res 30(1):95–104PubMedCrossRef
16.
17.
Yokoyama WM, Plougastel BF (2003) Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 3(4):304–16PubMedCrossRef
18.
19.
Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98(20):11521–6PubMedPubMedCentralCrossRef
20.
21.
Farrell HE, Davis-Poynter NJ, Andrews DM, Degli-Esposti MA (2002) Function of CMV-encoded MHC class I homologues. Curr Top Microbiol Immunol 269:131–51PubMed
22.
Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML (1997) A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7(2):273–82PubMedCrossRef
23.
Leong CC, Chapman TL, Bjorkman PJ, Formankova D, Mocarski ES, Phillips JH, Lanier LL (1998) Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med 187(10):1681–7PubMedPubMedCentralCrossRef
24.
Prod’homme V, Griffin C, Aicheler RJ, Wang EC, McSharry BP, Rickards CR, Stanton RJ, Borysiewicz LK, Lopez-Botet M, Wilkinson GW, Tomasec P (2007) The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells. J Immunol 178(7):4473–81PubMedCrossRef
25.
Wagner CS, Riise GC, Bergstrom T, Karre K, Carbone E, Berg L (2007) Increased expression of leukocyte Ig-like receptor-1 and activating role of UL18 in the response to cytomegalovirus infection. J Immunol 178(6):3536–43PubMedCrossRef
26.
Lopez-Botet M, Llano M, Ortega M (2001) Human cytomegalovirus and natural killer-mediated surveillance of HLA class I expression: a paradigm of host-pathogen adaptation. Immunol Rev 181:193–202PubMedCrossRef
27.
Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW (2000) Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287(5455):1031PubMedCrossRef
28.
Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M, Weiss EH (2000) Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 164(10):5019–22PubMedCrossRef
29.
Scalzo AA, Fitzgerald NA, Simmons A, La Vista AB, Shellam GR (1990) Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J Exp Med 171(5):1469–83PubMedCrossRef
30.
Scalzo AA, Fitzgerald NA, Wallace CR, Gibbons AE, Smart YC, Burton RC, Shellam GR (1992) The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J Immunol 149(2):581–9PubMedCrossRef
31.
Brown MG, Dokun AO, Heusel JW, Smith HR, Beckman DL, Blattenberger EA, Dubbelde CE, Stone LR, Scalzo AA, Yokoyama WM (2001) Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 292(5518):934–7PubMedCrossRef
32.
Daniels KA, Devora G, Lai WC, O’Donnell CL, Bennett M, Welsh RM (2001) Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J Exp Med 194(1):29–44PubMedPubMedCentralCrossRef
33.
Lee SH, Girard S, Macina D, Busa M, Zafer A, Belouchi A, Gros P, Vidal SM (2001) Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet 28(1):42–5PubMedCrossRef
34.
Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL (2002) Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296(5571):1323–6PubMedCrossRef
35.
Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV, Iizuka K, Furukawa H, Beckman DL, Pingel JT, Scalzo AA, Fremont DH, Yokoyama WM (2002) Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci USA 99(13):8826–31PubMedPubMedCentralCrossRef
36.
Adams EJ, Juo ZS, Venook RT, Boulanger MJ, Arase H, Lanier LL, Garcia KC (2007) Structural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptors. Proc Natl Acad Sci USA 104(24):10128–33PubMedPubMedCentralCrossRef
37.
Voigt V, Forbes CA, Tonkin JN, Degli-Esposti MA, Smith HR, Yokoyama WM, Scalzo AA (2003) Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc Natl Acad Sci USA 100(23):13483–8PubMedPubMedCentralCrossRef
38.
French AR, Pingel JT, Wagner M, Bubic I, Yang L, Kim S, Koszinowski U, Jonjic S, Yokoyama WM (2004) Escape of mutant double-stranded DNA virus from innate immune control. Immunity 20(6):747–56PubMedCrossRef
39.
Desrosiers MP, Kielczewska A, Loredo-Osti JC, Adam SG, Makrigiannis AP, Lemieux S, Pham T, Lodoen MB, Morgan K, Lanier LL, Vidal SM (2005) Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat Genet 37(6):593–9PubMedPubMedCentralCrossRef
40.
Adam SG, Caraux A, Fodil-Cornu N, Loredo-Osti JC, Lesjean-Pottier S, Jaubert J, Bubic I, Jonjic S, Guenet JL, Vidal SM, Colucci F (2006) Cmv4, a new locus linked to the NK cell gene complex, controls innate resistance to cytomegalovirus in wild-derived mice. J Immunol 176(9):5478–85PubMedCrossRef
41.
Rodriguez M, Sabastian P, Clark P, Brown MG (2004) Cmv1-independent antiviral role of NK cells revealed in murine cytomegalovirus-infected New Zealand White mice. J Immunol 173(10):6312–8PubMedCrossRef
42.
Cerwenka A, Lanier LL (2003) NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61(5):335–43PubMedCrossRef
43.
Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E, Raulet DH (2002) Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 3(12):1142–9PubMedCrossRef
44.
Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M (2002) NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 3(12):1150–5PubMedCrossRef
45.
Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, Mullberg J, Rousseau AM, Ulrich D, Armitage R (2001) ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol 31(5):1428–37PubMedCrossRef
46.
Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14(2):123–33PubMedCrossRef
47.
Chalupny NJ, Rein-Weston A, Dosch S, Cosman D (2006) Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 346(1):175–81PubMedCrossRef
48.
Krmpotic A, Hasan M, Loewendorf A, Saulig T, Halenius A, Lenac T, Polic B, Bubic I, Kriegeskorte A, Pernjak-Pugel E, Messerle M, Hengel H, Busch DH, Koszinowski UH, Jonjic S (2005) NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med 201(2):211–20PubMedPubMedCentralCrossRef
49.
Krmpotic A, Busch DH, Bubic I, Gebhardt F, Hengel H, Hasan M, Scalzo AA, Koszinowski UH, Jonjic S (2002) MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol 3(6):529–35PubMedCrossRef
50.
Hasan M, Krmpotic A, Ruzsics Z, Bubic I, Lenac T, Halenius A, Loewendorf A, Messerle M, Hengel H, Jonjic S, Koszinowski UH (2005) Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J Virol 79(5):2920–30PubMedPubMedCentralCrossRef
51.
Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES, Lanier LL (2003) NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 197(10):1245–53PubMedPubMedCentralCrossRef
52.
Lodoen MB, Abenes G, Umamoto S, Houchins JP, Liu F, Lanier LL (2004) The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med 200(8):1075–81PubMedPubMedCentralCrossRef
53.
Lenac T, Budt M, Arapovic J, Hasan M, Zimmermann A, Simic H, Krmpotic A, Messerle M, Ruzsics Z, Koszinowski UH, Hengel H, Jonjic S (2006) The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med 203(8):1843–50PubMedPubMedCentralCrossRef
54.
Thale R, Lucin P, Schneider K, Eggers M, Koszinowski UH (1994) Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol 68(12):7757–65PubMedPubMedCentralCrossRef
55.
Crnkovic-Mertens I, Messerle M, Milotic I, Szepan U, Kucic N, Krmpotic A, Jonjic S, Koszinowski UH (1998) Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol 72(2):1377–82PubMedPubMedCentralCrossRef
56.
Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Hahn G, Goldman-Wohl D, Greenfield C, Yagel S, Hengel H, Altuvia Y, Margalit H, Mandelboim O (2007) Host immune system gene targeting by a viral miRNA. Science 317(5836):376–81PubMedPubMedCentralCrossRef
57.
Campbell JA, Trossman DS, Yokoyama WM, Carayannopoulos LN (2007) Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D. J Exp Med 204(6):1311–7PubMedPubMedCentralCrossRef
58.
Garrity D, Call ME, Feng J, Wucherpfennig KW (2005) The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci USA 102(21):7641–6PubMedPubMedCentralCrossRef
59.
Eagle RA, Trowsdale J (2007) Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 7(9):737–44PubMedCrossRef
60.
Ziegler H, Thale R, Lucin P, Muranyi W, Flohr T, Hengel H, Farrell H, Rawlinson W, Koszinowski UH (1997) A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 6(1):57–66PubMedCrossRef
61.
Zou Z, Nomura M, Takihara Y, Yasunaga T, Shimada K (1996) Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells: a novel cDNA family encodes cell surface proteins sharing partial homology with MHC class I molecules. J Biochem (Tokyo) 119(2):319–28PubMedCrossRef
62.
Wagner M, Gutermann A, Podlech J, Reddehase MJ, Koszinowski UH (2002) Major histocompatibility complex class I allele-specific co-operative and competitive interactions between immune evasion proteins of cytomegalovirus. J Exp Med 196(6):805–16PubMedPubMedCentralCrossRef
63.
Dell’Angelica EC (2001) Clathrin-binding proteins: got a motif? Join the network! Trends Cell Biol 11(8):315–8PubMedCrossRef
64.
Mintern JD, Klemm EJ, Wagner M, Paquet ME, Napier MD, Kim YM, Koszinowski UH, Ploegh HL (2006) Viral interference with B7-1 costimulation: a new role for murine cytomegalovirus fc receptor-1. J Immunol 177(12):8422–31PubMedCrossRef
Metadata
Title
Murine cytomegalovirus regulation of NKG2D ligands
Authors
Tihana Lenac
Jurica Arapović
Luka Traven
Astrid Krmpotić
Stipan Jonjić
Publication date
01-06-2008
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2/2008
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-008-0080-7

Other articles of this Issue 2/2008

Medical Microbiology and Immunology 2/2008 Go to the issue

Review

Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection

Review

CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model

Review

The history of cytomegalovirus and its diseases

Original Investigation

Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques

Original Investigation

Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues

Review

Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits